|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
 Congestive Heart FailureVolume 13 Issue 1, Pages 48 - 52 Published Online: 2 Feb 2007 © 2010 Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 152K) | Related Articles | Citation Tracking  Review Paper B-Type Natriuretic Peptide: A Critical Review Copyright 2007 Le Jacq (CHF. 2007;13:48–52) ABSTRACTNatriuretic peptides have been used as tools for diagnosis and risk stratification in patients with heart failure, myocardial infarction, and unstable coronary syndromes, as well as in the general population. The biology of intra-assay and intraindividual variations of plasma natriuretic peptide levels is still not clearly understood despite their broad adoption in clinical practice. Interpretation of plasma natriuretic peptide levels therefore requires availability of the clinical context as well as considerations of various confounders. It is clear that high plasma natriuretic peptide levels can be highly suggestive of underlying myocardial disease, although a specific underlying cause cannot be identified based on the test results. The potential use of natriuretic peptide levels to monitor and guide patient management or detect subclinical disease states is currently under investigation. Manuscript received September 4, 2006; revised November 6, 2006; | 
|
